Squawk Pod Johnson & Johnson’s Next Split & “1929” Hits Shelves 10/14/25
Oct 14, 2025
Joaquin Duato, the CEO of Johnson & Johnson, shares insights on the company’s strong earnings and a strategic split of its orthopedics business. He discusses the impact of FDA warnings on their treatment Carvykti and highlights exciting new products in the pipeline. Meanwhile, Andrew Ross Sorkin, a prominent financial journalist, promotes his new book, 1929, which delves into the dramatic stock market crash and its lasting effects on capitalism. He shares behind-the-scenes stories and the challenges of researching this tumultuous period.
AI Snips
Chapters
Books
Transcript
Episode notes
China-U.S. Maritime Tensions Escalate
- U.S.-China maritime tit-for-tat escalated with reciprocal port fee increases and sanctions on shipbuilding subsidiaries.
- Andrew Ross Sorkin highlights how trade tensions are expanding into port charges and corporate sanctions.
J&J Entering Accelerated Growth Era
- Johnson & Johnson reported a strong quarter and says it's entering an era of accelerated growth driven by pharma and medtech.
- Excluding Stelara, pharmaceutical growth was 16% with 11 brands in double digits, signaling durable pipeline strength.
Carvykti Remains Core Multiple Myeloma Win
- Carvykti is a transformational CAR-T with rapid uptake despite new safety warnings for rare intestinal events.
- J&J highlights 8,500 treated patients and calls Carvykti the most successful CAR-T launch ever with strong risk-benefit feedback from clinicians.
